EGFR and non-small cell lung carcinoma: Additionally, in a case report of EGFR-mutant NSCLC with a high PD-L1 TPS of 80% [24], pCR was achieved after neoadjuvant immunochemotherapy, indicating the promise of this combination regimen in EGFR-mutant NSCLCs, especially for those with concurrent high PD-L1 expression.